3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Unknown
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
19
Gastrointestinal
6
Breast
5
Thoracic
4
Sarcoma
3
CNS
3
Lymphoid
2
Gynecologic
2
Plasma cell
1
Genitourinary
1
Dermatologic
1
Conditions
Melanoma
5
Carcinoma, Non-Small-Cell Lung
4
Skin Neoplasms
3
Pancreatic Neoplasms
3
Neoplasm Metastasis
3
Colorectal Neoplasms
3
Carcinoma, Renal Cell
3
Breast Neoplasms
3
Sarcoma
2
Ovarian Neoplasms
2
Neoplasms
2
Lymphoma, T-Cell, Cutaneous
2
Colonic Neoplasms
2
Carcinoma, Merkel Cell
2
Zollinger-Ellison Syndrome
1
Waldenstrom Macroglobulinemia
1
Vipoma
1
Triple Negative Breast Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Somatostatinoma
1
Sezary Syndrome
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pheochromocytoma
1
Non functioning pancreatic endocrine tumor
1
Neuroendocrine Tumors
1
Mycosis Fungoides
1
Interventions
pembrolizumab
59
Nivolumab
19
atezolizumab
8
Ipilimumab
8
Docetaxel
7
avelumab
6
Paclitaxel
6
cemiplimab
5
Specimen Handling
5
Cyclophosphamide
5
Biopsy
5
Taxes
4
Pemetrexed
4
Magnetic Resonance Spectroscopy
4
Interleukin-2
4
Gemcitabine
4
Carboplatin
4
utomilumab
3
epacadostat
3
durvalumab
3
Radiotherapy
3
Cisplatin
3
Cetuximab
3
tremelimumab
2
tislelizumab
2
sargramostim
2
poly ICLC
2
obinutuzumab
2
fludarabine
2
enzalutamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Squamous Cell Carcinoma of Head and Neck
×
Capecitabine
×
Dermatologic
×
Clear all
NCT03775525
2022-12-23
GEN602
Genzada Pharmaceuticals USA, Inc.
Phase 1
Unknown
127 enrolled